Alder BioPharmaceuticals, Inc. a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of positive data from its Phase 2b clinical trial evaluating eptinezumab (formerly ALD403) for the prevention of migraine.
Key findings from the study showed that chronic migraine patients treated with a single infusion of eptinezumab (ALD403) experienced a significant reduction in migraine days as measured by 75% responder rates, with maximum efficacy in 1 to 4 weeks that was maintained through 12-weeks. Post hoc analysis of the trial data also suggested that a single administration led to a clinically meaningful reduction in the percentage of patients experiencing migraine within 24 to 48 hours post infusion. These data and additional study results are the topic of a podium presentation titled “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403 (Eptinezumab), an Anti-CGRP Peptide Antibody, in the Prevention of Chronic Migraine” presented at the 69th Annual American Academy of Neurology (AAN) meeting in Boston.
“Eptinezumab has demonstrated its potential as a preventative treatment for migraine in clinical trials to date. The data from these trials, and the fact that it’s the only anti-CGRP monoclonal antibody being developed for administration via infusion, suggest that, if approved, eptinezumab may be an important therapeutic option for patients needing fast onset to migraine prevention that is sustained for 12 weeks for the treatment of their migraines,” said Jeffrey Smith, M.D., FRCP, a founder of Alder and managing director of Alder’s Irish subsidiary, Alder BioPharmaceuticals Limited.
Randall C. Schatzman, Ph.D., president and chief executive officer of Alder, added, "These new data further demonstrate the differentiated delivery and clinical profile of eptinezumab for migraine prevention. We are on track to report top-line results from our first Phase 3 pivotal trial of eptinezumab later this quarter. Our focus is on moving through the clinical development program toward a BLA filing next year so that eptinezumab, if approved, can meet patient needs as a potentially transformative migraine prevention therapy.”
The study was a parallel group, double-blind, randomized, placebo controlled, dose-ranging Phase 2b trial to evaluate the efficacy, safety and pharmacokinetics of eptinezumab (ALD403) administered intravenously in patients with chronic migraine. The study enrolled 616 patients across 90 sites, stratified into four experimental dose groups: 10 mg ALD403, 30mg ALD403, 100 mg ALD403, 300 mg ALD403, and a placebo group. The primary endpoint was the reduction in migraine days as measured by the 75% responder rates from baseline to week 12, and secondary endpoints included the evaluation of safety and pharmacokinetics.
.png)
